A Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants with Mild-to-Moderate Alzheimer's Disease (Lauriet).
Cecilia MonteiroBalazs TothFlavia BrunsteinAshwini BobbalaSeema DattaRyan CenicerosSandra Sanabria BohorquezVeronica AnaniaKristin WildsmithStephen SchauerJulie LeeMichael DoltonVidya RamakrishnanDaniel AbramzonEdmond Tengnull nullPublished in: Neurology (2023)
The Lauriet study is registered on ClinicalTrials.gov, NCT03828747 (status: active, not recruiting), and EudraCT 2018-003398-87.